Hence, the TMPRSS2-ERG fusion gene in prostate cancer could be considered for use as a noninvasive tumor marker for therapy assessment, risk stratification, and relapse detection to improve personalized therapy strategies. This evidence concerns the gene TMPRSS2 and neoplasm.